Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection

Medical Hypotheses

Volumn 81, Issue 1, 2013, Pages 125-130

  Alonso Villaverde, Carlos ^a   Menéndez, Javier A ^b   Joven, Jorge ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; METFORMIN; VORINOSTAT;

ARTICLE; AUTOPHAGY; CD4+ T LYMPHOCYTE; CELL DEATH; FATTY ACID SYNTHESIS; GENOMIC INSTABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; METABOLIC STRESS; VIRUS GENE; VIRUS LATENCY;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHLOROQUINE; GENOMIC INSTABILITY; HIV INFECTIONS; HIV-1; HUMANS; METFORMIN; MODELS, THEORETICAL; STRESS, PHYSIOLOGICAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878558843     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.009     Document Type: Article

References (38)

1. Havlir D.V., Strain M.C., Clerici M., et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003, 77:11212-11219.
2. Palmer S. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy. Curr Opin HIV AIDS 2013, 8:87-92.
3. Joven J., Menendez J.A. Human immunodeficiency virus infection as a model of premature aging: perspectives and implications. Med Clin (Barc) 2012, 139:249-251.
4. Alonso-Villaverde C., Coll B., Parra S., et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004, 110:2204-2209.
5. Lahuerta M., Ue F., Hoffman S., Elul B., et al. The problem of late ART initiation in sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?. J Health Care Poor Underserved 2013, 24:359-383.
6. Emdin C., Millson P. A systematic review evaluating the impact of task shifting on access to antiretroviral therapy in sub-Saharan Africa. Afr Health Sci 2012, 12:318-324.
7. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
8. Hütter G., Nowak D., Mossner M., et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
9. Archin N.M., Liberty A.L., Kashuba A.D., et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.
10. Thompson M.A., Aberg J.A., Hoy J.F., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
11. Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683.
12. Vazquez-Martin A., López-Benet E., Cufí S., et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 2011, 14:212-223.
13. Schultze S.M., Hemmings B.A., Niessen M., Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 2012, 14:e1.
14. Loehberg C.R., Strissel P.L., Dittrich R., et al. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 2012, 83:480-488.
15. Fan Q.W., Cheng C., Hackett C., et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010, 3(147):ra81.
16. Gary-Bobo G., Houssaini A., Amsellem V., et al. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 2010, 122:1937-1947.
17. Killian M.S. Dual role of autophagy in HIV-1 replication and pathogenesis. AIDS Res Ther 2012, 9(1):16.
18. Zhou S., Zhao L., Kuang M., et al. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. Cancer Lett 2012, 323:115-127.
19. Abraham R.T., Tibbetts R.S. Cell biology. Guiding ATM to broken DNA. Science 2005, 308:510-511.
20. Vazquez-Martin A., Oliveras-Ferraros C., Cufí S., et al. Metformin activates an Ataxia Telangiectasia Mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 2011, 10:1499-1501.
21. Menendez J.A., Cufí S., Oliveras-Ferraros C., et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011, 3:1063-1077.
22. van Wijk J.P.H., de Koning E.J.P., Cabezas M.C., et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337-346.
23. Joven J., Menéndez J., Fernandez-Sender L., et al. Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. HIV Med 2013, 14:233-240.
24. Zhou K., Bellenguez C., Spencer C.C., et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43:117-120.
25. Ariumi Y., Trono D. Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev Function. J Virol 2006, 80:2445-2452.
26. Mankouri J., Tedbury P.R., Gretton S., et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci USA 2010, 107:11549-11554.
27. Speakman J.R., Mitchell S.E. Caloric restriction. Mol Aspects Med 2011, 32:159-221.
28. Moser T.S., Schieffer D., Cherry S. AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis. PLoS Pathog 2012, 8:e1002661.
29. Rasheed S., Yan J.S., Lau A., Chan A.S. HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study. PLoS One 2008, 3(8):e3003.
30. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
31. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 2002, 41:27-65.
32. Paton N.I., Goodall R.L., Dunn D.T., et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012, 308:353-361.
33. Marfurt J., Chalfein F., Prayoga P., et al. Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother 2011, 55:961-966.
34. Carew J.S., Medina E.C., Esquivel J.A., et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010, 14:2448-2459.
35. Rao R., Balusu R., Fiskus W., et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012, 11:973-983.
36. Thomas S., Thurn K.T., Biçaku E., Marchion D.C., Münster P.N. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 2011, 130:437-447.
37. Jiang G., Espeseth A., Hazuda D.J., Margolis D.M. C-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 2007, 81:10914-10923.
38. Menendez J.A., Oliveras-Ferraros C., Cufí S., et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012, 11:2782-2792.